| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| BioNTech SE | Pumitamig + BNT325/DB-1305 (TROP2-ADC | TNBC | Phase 2 | Ongoing | Intravenous | Oncology |
| BioNTech SE | BNT327-02 | 1-2L Metastatic Triple-negative breast cancer (TNBC) | Phase 2 | Data Released | Intravenous | Oncology |
| BioNTech SE | Gotistobart (BNT316/ONC-392) with lutetium Lu 177 vipivotide tetraxetan (Lu 177) | Metastatic castration-resistant prostate cancer (mCRPC) | Phase 2 | Ongoing | Intravenous | Oncology |
| BioNTech SE | Combined influenza and COVID-19 Vaccine | Vaccine candidate against influenza and COVID-19 | Phase 3 | Data Released | Intramuscular | COVID-19 |
| BioNTech SE | Pumitamig | 1L HNSCC | Phase 3 | Trial Planned | Intravenous | Oncology |
| BioNTech SE | Pumitamig - (China trial) | 1L MSS-CRC | Phase 2 | Ongoing | Intravenous | Oncology |
| BioNTech SE | Pumitamig | 1L HER2- PD-L1+ gastric cancer | Phase 3 | Trial Planned | Intravenous | Oncology |
| BioNTech SE | BNT162b5 | COVID-19 vaccine | Phase 2 | Intramuscular | COVID-19 |